会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Methods for protecting tissues and organs from ischemic damage
    • 保护组织和器官免受缺血损伤的方法
    • US5443836A
    • 1995-08-22
    • US33310
    • 1993-03-15
    • James M. DowneyKevin Mullane
    • James M. DowneyKevin Mullane
    • A61F2/02A61K9/14A61K9/20A61K9/48A61M31/00C07H20060101
    • A61K31/70Y10S514/936
    • Methods for protecting tissues and organs including the heart central nervous system, and kidney from ischemic damage are described and claimed based upon the recognition that protection against infarction is mediated by A3 rather than A1 adenosine receptors, as was previously thought, and that the receptor mediating protection in other organs and tissues has not been defined. Methods for selectively stimulating A3 adenosine receptors are described and claimed, as such selection is shown to prevent or substantially reduce cell death resulting from ischemia with or without reperfusion in humans. According to this invention, the A3 adenosine receptor is selectively stimulated by administering a compound which is an A3 adenosine receptor-selective agonist. Prevention of tissue death is also achieved by administering a compound which is a non-selective adenosine receptor agonist together with compounds that act as antagonists to the A1 and A2 adenosine receptors.
    • 基于以前认为由APC而不是A1腺苷受体介导的对梗塞的保护的认识描述和要求保护包括心脏中枢神经系统在内的组织和器官以及来自缺血性损伤的肾脏的方法,并且受体介导 其他器官和组织的保护尚未定义。 描述和要求保护选择性刺激A3腺苷受体的方法,因为这样的选择被证明可预防或显着减少由于在人或不伴有再灌注的局部缺血导致的细胞死亡。 根据本发明,通过给予作为A3腺苷受体选择性激动剂的化合物来选择性地刺激A3腺苷受体。 还通过将作为非选择性腺苷受体激动剂的化合物与作为Aβ和腺苷受体的拮抗剂的化合物一起施用来预防组织死亡。
    • 6. 发明授权
    • Method for diminishing myocardial infarction using protein phosphatase
inhibitors
    • 使用蛋白磷酸酶抑制剂减少心肌梗死的方法
    • US5914242A
    • 1999-06-22
    • US941964
    • 1997-10-01
    • Richard Eric HonkanenJames M. Downey
    • Richard Eric HonkanenJames M. Downey
    • A61K31/665A61K38/00C12Q1/42C12Q1/00G01N33/53
    • A61K31/665A61K38/005C12Q1/42
    • Fostriecin and a compounds structurally related to fostriecin diminish myocardial infarction and delay the onset of cell injury in an ischemic heart. There is a strong correlation between myocardial protection and the inhibition of certain serine/threonine protein phosphatases. The present invention is drawn to a method for administering fostriecin as a pharmacological compound to reduce the size of a myocardial infarction. Further, administration of fostriecin is useful also as an adjunct therapy to treatment with thrombolytic agents or angioplasty to limit the size of infarction. The most advantageous feature of the method of the present invention is that administration of fostriecin diminishes infarct volume and cell injury even when added after ischemia conditions occurred. In addition to the use of the method of the present invention for limiting damage due to myocardial infarction, the method of the present invention can be employed to delay damage associated with tissue storage for organ transplantation.
    • 福斯特因及其与fostriecin结构相关的化合物减少心肌梗塞并延缓缺血性心脏细胞损伤的发生。 心肌保护与某些丝氨酸/苏氨酸蛋白磷酸酶的抑制有很强的相关性。 本发明涉及一种施用作为药理化合物的骨菌素以减少心肌梗塞的大小的方法。 此外,对于治疗血栓溶解剂或血管成形术来限制梗塞的大小,福斯特林的给药也可用作辅助治疗。 本发明方法的最有利特征在于,即使在局部缺血病症发生后加入,三聚氰胺的施用也会降低梗死体积和细胞损伤。 除了使用本发明的方法以限制由于心肌梗塞引起的损伤之外,本发明的方法可用于延迟与用于器官移植的组织储存有关的损伤。
    • 7. 发明授权
    • Methods for protecting tissues and organs from ischemic damage
    • 保护组织和器官免受缺血损伤的方法
    • US5573772A
    • 1996-11-12
    • US214942
    • 1994-03-17
    • James M. DowneyKevin M. Mullane
    • James M. DowneyKevin M. Mullane
    • A61F2/02A61K9/14A61K9/20A61K9/48A61M31/00C07H20060101
    • A61K31/70Y10S514/936
    • Methods for protecting tissues and organs including the heart central nervous system, and kidney from ischemic damage are described and claimed based upon the recognition that protection against infarction is mediated by A3 rather than A1 adenosine receptors, as was previously thought, and that the receptor mediating protection in other organs and tissues has not been defined. Methods for selectively stimulating A3 adenosine receptors are described and claimed, as such selection is shown to prevent or substantially reduce cell death resulting from ischemia with or without reperfusion in humans. According to this invention, the A3 adenosine receptor is selectively stimulated by administering a compound which is an A3 adenosine receptor-selective agonist. Prevention of tissue death is also achieved by administering a compound which is a non-selective adenosine receptor agonist together with compounds that act as antagonists to the A1 and A2 adenosine receptor.
    • 基于以前认为由APC而不是A1腺苷受体介导的对梗塞的保护的认识描述和要求保护包括心脏中枢神经系统在内的组织和器官以及来自缺血性损伤的肾脏的方法,并且受体介导 其他器官和组织的保护尚未定义。 描述和要求保护选择性刺激A3腺苷受体的方法,因为这样的选择被证明可预防或显着减少由于在人或不伴有再灌注的局部缺血导致的细胞死亡。 根据本发明,通过给予作为A3腺苷受体选择性激动剂的化合物来选择性地刺激A3腺苷受体。 还通过将作为非选择性腺苷受体激动剂的化合物与作为Aβ和腺苷受体的拮抗剂的化合物一起施用来预防组织死亡。